ArticleClinical kidney journal2026
Intra-individual fluctuations in alkaline phosphatase predict mortality and CKD progression: insights from a large CKD cohort.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated alkaline phosphatase (ALP) levels are associated with mortality. However, the significance of ALP variability, particularly in chronic kidney disease (CKD), has not been well explored. This study examined the associations of baseline ALP and its variability with all-cause mortality and end-stage kidney disease (ESKD) in patients with CKD. Methods: This retrospective cohort study analyzed data from tertiary hospitals in Taiwan and Korea (2001-2021). Adults with CKD, defined by at least two estimated glomerular filtration rate (eGFR) values <60 ml/min/1.73 m Results: In the baseline ALP cohort ( Conclusion: Given the significant impact of ALP levels and their variability on mortality and kidney disease progression, targeted monitoring and stabilization of ALP over time may help improve long-term outcomes in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.